Naturally occurring hyperactive variants of human parkin

Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disease in the world. Although most cases are sporadic and occur later in life, 10–15% of cases are genetic. Loss-of-function mutations in the ring-between-ring E3 ubiquitin ligase parkin, encoded by the PRKN gene, cause autosomal recessive forms of early onset PD. Together with the kinase PINK1, parkin forms a mitochondrial quality control pathway that tags damaged mitochondria for clearance. Under basal conditions, parkin is inhibited and compounds that increase its activity have been proposed as a therapy for PD. Recently, several naturally occurring hyperactive parkin variants were identified, which increased mitophagy in cultured cells. Here, we validate the hyperactivities of these variants in vitro and compare the levels of activity of the variants to those of the wild-type and the well-characterized hyperactive variant, W403A. We also study the effects of mutating the parkin ACT (activating element) on parkin activity in vitro. This work advances our understanding of the pathogenicity of parkin variants and is an important first step in the design of molecules to increase parkin activity.

The activities of five naturally occurring parkin variants were characterized in vitro and compared to the well-characterized hyperactive variant, W403A. Mutations in the parkin ACT (activating element) had a small but measurable effect on activity.